New England Council member Boston Scientific recently received Food and Drug Administration approval of their new Innova Vascular Self-Expanding Stent System.
The stent will be used as a treatment for patients with narrowing or blockages in the superficial femoral artery or proximal popliteal artery. Without treatment, the narrowing or blockages in those arteries can lead to peripheral artery disease which affects more than 200 million people worldwide and can lead to painful ulcers, infections, or amputation of the toes or feet. Boston Scientific has begun a full commercial launch of the Innova Stent System.
President of Peripheral Interventions at Boston Scientific Jeff Mirviss said, “This is an important therapy for a disease that can have life-changing consequences, including limb amputation. The Innova and the Eluvia Stent Systems together demonstrate our commitment to improving health outcomes in the treatment of a disease affecting more than 200 million people worldwide.”
The New England Council congratulates Boston Scientific on the approval of their new stent.
For more information, see this Worcester Business Journal article or the Boston Scientific press release.